CliffBio
small molecule

LICART

DICLOFENAC EPOLAMINE

Loss of exclusivityFebruary 2035latest FDA-listed patent expiry
CompanyIBSA Institut Biochimique →View the full company profile on CliffBio

Drug detail

Brand nameLICART
Active ingredientDICLOFENAC EPOLAMINE
Strength1.3%
Dosage formSYSTEM
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2018
Marketing statusRX

Listed patents

PatentExpiresType
11351133February 2035use U-3393
11344520February 2035use U-3393

Regulatory exclusivity

CodeExpires
NPPMarch 2029

More from IBSA Institut Biochimique

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LICART patent cliff — loss of exclusivity February 2035 | CliffBio